Enhancing SERCA2 expression or activity is a promising strategy in the gene therapy for heart failure (Hajjar et al., 1998; Del Monte et al., 2001; Sakata et al., 2007; Kawase et al., 2008). The gene discussed is ATP2A2; the disease is heart failure.